Stagezero Life - SZLSF STOCK NEWS

StageZero Life Sciences has launched its BORDERPASS™ COVID-19 RT-PCR saliva test kits available in over 400 Sobeys Inc. pharmacies across Canada. This innovative testing solution enables travelers to collect samples conveniently at home or hotels under video supervision. Results are provided within 24 hours of sample arrival. The BORDERPASS™ test is accepted at borders in Canada, the U.S., and internationally. This offering aligns with StageZero's Global Growth Strategy and is set to meet increasing travel demands during the holiday season.

StageZero Life Sciences has launched its ARISTOTLE® multi-cancer blood test in the Greater Toronto Area. This innovative test is the first mRNA multi-cancer panel that screens for several cancers from one blood sample with high sensitivity and specificity. The test targets multiple cancer types, including breast, ovarian, and colorectal cancers, aiding in early detection, which is crucial for successful treatment. The availability of this test is in collaboration with local clinics and is part of StageZero's Global Growth Strategy.

StageZero Life Sciences has launched the BORDERPASS™ COVID-19 RT-PCR saliva test, allowing travelers to conveniently self-collect samples from home, office, or hotel. This service is particularly timely with travel restrictions easing between the U.S. and Canada, where a negative PCR test is necessary for entry. The test kits, available for both individual and corporate purchases, ensure results are received within 24 hours. StageZero is enhancing its offerings in molecular diagnostics, focusing on cancer detection and management.

StageZero Life Sciences reported Q3 2021 revenue of $0.68 million, down from $1.46 million a year ago, with a net loss of $2.2 million. The company announced the acquisition of CareOncology and initiated integrated programs for its proprietary multi-cancer blood test, Aristotle. Despite revenue declines, management emphasizes the potential for significant patient outcome improvements and the establishment of an on-site clinic in Richmond, Virginia. The company is focused on enhancing its cancer detection capabilities within the evolving healthcare sector.

StageZero Life Sciences (TSX:SZLS, OTCQB:SZLSF) has announced a partnership with Teen Cancer America to enhance cancer detection and treatment for adolescents and young adults. In 2021, an estimated 88,000 individuals in this age group will be diagnosed with cancer, with over 9,000 fatalities. The collaboration will focus on awareness campaigns and health economics research, along with clinical studies for earlier detection of testicular, brain, and colorectal cancers. StageZero's Aristotle test is notable for its multi-cancer screening capabilities. This initiative aims to improve outcomes and survival rates for younger cancer patients.

StageZero Life Sciences has appointed Richard Huston to its Board of Directors as part of the Health Clinics acquisition, which closed on September 2, 2021. The company aims to enhance its board's skill set following the acquisition. A special shareholders meeting is scheduled for December 9, 2021, to approve contingent compensation for Health Clinics in shares or royalties. The acquisition involves issuing 15 million shares upon closing and an additional 8 million shares tied to achieving $4 million in revenue from the AVRT program between September 2021 and December 2022.

StageZero Life Sciences (TSX:SZLS) (OTCQB:SZLSF) will announce its Q3 2021 operational results on November 15, 2021, after market close. A conference call is scheduled for November 16, 2021, at 8:30 a.m. EST to discuss the results and business developments. The company focuses on enhancing cancer detection and management through advanced diagnostics like the multi-cancer panel test Aristotle™, validated in over 9,000 patients. StageZero operates a CAP accredited lab in Virginia and also provides COVID-19 PCR testing.

StageZero Life Sciences has established an on-site clinic in Richmond, Virginia, providing direct access to its multi-cancer blood test Aristotle. This test utilizes proprietary mRNA technology to screen for various cancers from a single blood sample. Available through the company's telehealth program AVRT, Aristotle is designed to be prescribed by physicians for early cancer detection. The announcement indicates a commitment to improving patient outcomes and expanding access to crucial diagnostic services in the Washington, D.C. area.

StageZero Life Sciences has commenced trading on the OTCQB under the symbol SZLSF, effective September 23, 2021, alongside its existing TSX listing. This milestone enhances investor access to the company, particularly from U.S. markets, as confirmed by CEO James Howard-Tripp. The OTCQB serves as a platform for early-stage companies, requiring them to meet rigorous reporting standards. StageZero specializes in early disease detection through its multi-cancer blood test, Aristotle, and operates a certified laboratory in Virginia.